Understanding Comorbidities: Impact on Biologic Treatment Selection

The focus shifts to the impact of comorbidities, particularly obesity and dyslipidemia, on the selection of psoriasis therapies. The dermatologists emphasize the importance of addressing obesity, noting its association with cardiovascular risks and metabolic syndrome. They discuss strategies for broaching the topic with patients, such as asking for permission to discuss weight loss and highlighting the potential benefits of weight loss medications in improving psoriasis severity. Additionally, they share anecdotal experiences of patients achieving significant improvements in psoriasis after losing weight. The dermatologists also mention the need for collaboration with primary care providers to manage obesity-related comorbidities effectively.

Regarding dyslipidemia, the dermatologists agree on the importance of monitoring lipid levels in psoriasis patients and initiating statin therapy if indicated. While some dermatologists prefer to directly start patients on statins, others opt to identify the issue and refer patients to their primary care providers for further management, citing the complexity of lipid management and the need for comprehensive care beyond dermatological expertise.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.